The Rationale of Estrogen Dose Reduction

This is a clinical reference text on the newest low-dose estrogen formulations for oral contraceptives. It contains five symposium-derived chapters by experts from the United States, United Kingdom, Sweden, Germany, and Ireland. Their contributions deal with the pill and society, an assessment of desogestrel as an oral contraceptive progestogen, the rationale of estrogen dose reduction, ovulation inhibition of low-dose oral contraceptives, and the clinical acceptability of the latest low-dose formulation for oral contraceptives containing 20 g ethinylestradiol plus 150 g desogestrel. Includes references and index. Publication Note: This volume is based upon the proceedings of an Organon-sponsored symposium at the 4th Congress of the European Society of Contraception, June, 1996, Barcelona, Spain.